Background: Almost half of all women will have at least one symptomatic urinary tract infection (UTI) in their lifetime. Although usually self-remitting, 74% of women contacting a health professional are prescribed an antibiotic, and in rare instances, they may progress to more severe infections. Therefore, the standard of care for the treatment of symptomatic uncomplicated UTIs is oral antibiotic therapy, which aims to achieve symptom resolution and prevent the development of complications such as pyelonephritis.
View Article and Find Full Text PDFGallbladder perforation in acalculous cholecystitis is rare and has a high mortality rate due to biliary peritonitis and sepsis. Here, we present a case series of successful laparoscopic management of Spontaneous gallbladder perforation in acalculous cholecystitis. In the first case, a 44-year-old male patient presented to the emergency room with a history of three days of fever with chills and acute pain in the abdomen for two days.
View Article and Find Full Text PDFBackground: Frailty is increasingly recognized as a perioperative risk for numerous surgical diseases. We applied the modified frailty index (mFI-11) to the National Inpatient Sample (NIS) for patients undergoing surgery for colorectal cancer (CRC).
Methods: We performed a retrospective analysis of the NIS (2015-2019) including CRC patients undergoing surgery.
The ongoing transition from a supply chain (SC) to net-zero emission (NZE) in SC performance must align with Sustainable Development Goal 13 to address climate change using life cycle assessment (LCA). Effective management of LCA significantly impacts an organization's competitiveness. With a lack of technology oversight and its connections with other enabling parameters that increase competitiveness, practices in the manufacturing industry remain limited.
View Article and Find Full Text PDFSmall cell neuroendocrine cancers share biologic similarities across tissue types, including transient response to platinum-based chemotherapy with rapid progression of disease. We report a phase 1b study of pembrolizumab in combination with platinum-based chemotherapy in 15 patients with stage III-IV small cell bladder (cohort 1) or small cell/neuroendocrine prostate cancers (cohort 2). Overall response rate (ORR) is 43% with two-year overall survival (OS) rate of 86% (95% confidence interval [CI]: 0.
View Article and Find Full Text PDF